Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

PHASE3TerminatedINTERVENTIONAL
Timeline

Start Date

March 31, 2001

Primary Completion Date

March 31, 2001

Study Completion Date

April 30, 2002

Conditions
Pancreatic CancerPerioperative/Postoperative Complications
Interventions
DRUG

vapreotide

PROCEDURE

conventional surgery

Trial Locations (18)

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

19104

University of Pennsylvania Cancer Center, Philadelphia

21231

Johns Hopkins Oncology Center, Baltimore

27710

Duke Comprehensive Cancer Center, Durham

33601

Moffett Cancer Center (South), Tampa

35294

University of Alabama Comprehensive Cancer Center, Birmingham

48109

Taubman Health Care Center, Ann Arbor

48201

Barbara Ann Karmanos Cancer Institute, Detroit

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic Cancer Center, Rochester

60153

Loyola University Medical Center, Maywood

60612

Rush-Presbyterian-St. Luke's Medical Center, Chicago

60637

University of Chicago Cancer Research Center, Chicago

98111

Virginia Mason Medical Center, Seattle

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

77555-1329

University of Texas Medical Branch, Galveston

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER